(NP (NP (NP Ablation/NN) (PP of/IN (NP (NP transplanted/VBN (ADJP HTLV-I/NN Tax-transformed/JJ) tumors/NNS) (PP in/IN (NP mice/NNS)))) (PP by/IN (NP (NP antisense/JJ inhibition/NN) (PP of/IN (NP NF-kappa/NN B/NN))))) (S -LCB-/-LRB- (NP-SBJ published/VBN erratum/NN) (VP appears/VBZ (PP in/IN (NP Science/NNP 1993/CD Mar/NNP 12/CD ;/: 259/CD -LRB-/-LRB- 5101/CD -RRB-/-RRB- :/: 1523/CD))) -RCB-/-RRB-))
(S (NP-SBJ (NP Mice/NNS) (ADJP transgenic/JJ (PP for/IN (NP the/DT (NP (NP human/JJ T/NN cell/NN leukemia/NN virus/NN) (PRN -LRB-/-LRB- (NP HTLV-I/NN) -RRB-/-RRB-)) Tax/NN gene/NN)))) (VP develop/VBP (NP (NP fibroblastic/JJ tumors/NNS) (SBAR (WHNP-1 that/WDT) (S (NP-SBJ *T*-1/-NONE-) (VP express/VBP (NP (ADJP NF-kappa/NN B-inducible/JJ) early/JJ genes/NNS)))))) ./.)
(S (NP-SBJ (NP (ADJP In/FW vitro/FW) inhibition/NN) (PP of/IN (NP NF-kappa/NN B/NN expression/NN)) (PP by/IN (NP antisense/JJ (NP (NP oligodeoxynucleotides/NNS) (PRN -LRB-/-LRB- (NP ODNs/NNS) -RRB-/-RRB-))))) (VP inhibited/VBD (NP (NP growth/NN) (PP of/IN (NP-COOD (NP these/DT culture-adapted/JJ Tax-transformed/JJ fibroblasts/NNS) (CONJP as/RB well/RB as/IN) (NP an/DT HTLV-I-transformed/JJ human/JJ lymphocyte/NN line/NN))))) ./.)
(S (PP In/IN (NP contrast/NN)) ,/, (NP-SBJ (NP antisense/JJ inhibition/NN) (PP of/IN (NP (NP Tax/NN) (NP itself/PRP)))) (VP had/VBD (NP no/DT apparent/JJ effect/NN) (PP on/IN (NP cell/NN growth/NN))) ./.)
(S (NP-SBJ (NP Mice/NNS) (VP treated/VBN (NP */-NONE-) (PP with/IN (NP (NP antisense/NN) (PP to/TO (NP NF-kappa/NN B/NN ODNs/NNS)))))) (VP showed/VBD (NP (NP rapid/JJ regression/NN) (PP of/IN (NP transplanted/VBN fibrosarcomas/NNS)))) ./.)
(S (NP-SBJ This/DT) (VP-COOD (VP suggests/VBZ (SBAR that/IN (S (NP-SBJ NF-kappa/NN B/NN expression/NN) (VP may/MD (VP be/VB (ADJP-PRD necessary/JJ (PP for/IN (NP (NP the/DT maintenance/NN) (PP of/IN (NP the/DT malignant/JJ phenotype/NN)))))))))) and/CC (VP provides/VBZ (NP (NP a/DT therapeutic/JJ approach/NN) (PP for/IN (NP HTLV-I-associated/JJ disease/NN))))) ./.)
